Tempest Therapeutics IncNASDAQ:TPST
- LAST PRICE1.3000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.3000/ 16
- Ask / Lots1.3300/ 3
- Open / Previous Close--- / 1.3000
- Day Range---
- 52 Week Range
- Volume2,841
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TPST |
|---|---|---|
| 09:32 ET | 18161 | 1.31 |
| 09:34 ET | 1250 | 1.289 |
| 09:36 ET | 3079 | 1.2899 |
| 09:38 ET | 743 | 1.2905 |
| 09:39 ET | 4552 | 1.3001 |
| 09:41 ET | 1500 | 1.2999 |
| 09:43 ET | 23921 | 1.291966 |
| 09:48 ET | 9672 | 1.32 |
| 09:50 ET | 3236 | 1.3107 |
| 09:52 ET | 2201 | 1.32 |
| 09:54 ET | 1275 | 1.315 |
| 09:56 ET | 5323 | 1.315 |
| 09:57 ET | 475 | 1.315 |
| 09:59 ET | 145 | 1.3113 |
| 10:01 ET | 1378 | 1.31 |
| 10:03 ET | 620 | 1.3196 |
| 10:06 ET | 3859 | 1.325 |
| 10:08 ET | 300 | 1.325 |
| 10:10 ET | 100 | 1.3201 |
| 10:12 ET | 100 | 1.3299 |
| 10:15 ET | 400 | 1.3205 |
| 10:17 ET | 100 | 1.325 |
| 10:19 ET | 1456 | 1.317 |
| 10:24 ET | 4100 | 1.31 |
| 10:26 ET | 1000 | 1.3112 |
| 10:30 ET | 300 | 1.31 |
| 10:32 ET | 278 | 1.32 |
| 10:33 ET | 2100 | 1.31 |
| 10:35 ET | 300 | 1.3198 |
| 10:37 ET | 300 | 1.3105 |
| 10:39 ET | 100 | 1.31 |
| 10:44 ET | 226 | 1.31 |
| 10:48 ET | 100 | 1.315 |
| 10:50 ET | 100 | 1.31 |
| 10:55 ET | 12026 | 1.3107 |
| 10:57 ET | 958 | 1.31 |
| 11:02 ET | 2120 | 1.3 |
| 11:04 ET | 100 | 1.3 |
| 11:09 ET | 200 | 1.3005 |
| 11:11 ET | 100 | 1.3 |
| 11:18 ET | 100 | 1.3 |
| 11:22 ET | 3700 | 1.31 |
| 11:24 ET | 200 | 1.31 |
| 11:26 ET | 102 | 1.3095 |
| 11:29 ET | 100 | 1.31 |
| 11:31 ET | 100 | 1.305 |
| 11:36 ET | 100 | 1.3 |
| 11:44 ET | 100 | 1.3 |
| 11:47 ET | 1000 | 1.3001 |
| 11:49 ET | 100 | 1.3 |
| 11:51 ET | 984 | 1.305 |
| 11:54 ET | 100 | 1.305 |
| 11:56 ET | 412 | 1.3 |
| 12:03 ET | 100 | 1.3 |
| 12:09 ET | 100 | 1.3 |
| 12:14 ET | 903 | 1.3 |
| 12:16 ET | 2900 | 1.3 |
| 12:18 ET | 350 | 1.2912 |
| 12:20 ET | 800 | 1.295 |
| 12:23 ET | 11039 | 1.29 |
| 12:25 ET | 100 | 1.29 |
| 12:30 ET | 150 | 1.2905 |
| 12:32 ET | 200 | 1.295 |
| 12:36 ET | 2100 | 1.29 |
| 12:38 ET | 100 | 1.29 |
| 12:39 ET | 700 | 1.2902 |
| 12:41 ET | 100 | 1.29 |
| 12:45 ET | 100 | 1.29 |
| 12:52 ET | 100 | 1.29 |
| 12:59 ET | 6675 | 1.28 |
| 01:01 ET | 200 | 1.2799 |
| 01:06 ET | 1000 | 1.275 |
| 01:08 ET | 7281 | 1.27 |
| 01:10 ET | 151 | 1.27 |
| 01:14 ET | 200 | 1.275 |
| 01:15 ET | 500 | 1.2797 |
| 01:17 ET | 100 | 1.275 |
| 01:21 ET | 300 | 1.2783 |
| 01:26 ET | 200 | 1.2799 |
| 01:28 ET | 1000 | 1.28 |
| 01:30 ET | 100 | 1.27 |
| 01:35 ET | 100 | 1.28 |
| 01:37 ET | 100 | 1.27 |
| 01:39 ET | 3209 | 1.275 |
| 01:44 ET | 200 | 1.27 |
| 01:50 ET | 10850 | 1.28 |
| 01:51 ET | 2310 | 1.2806 |
| 01:53 ET | 300 | 1.285 |
| 01:55 ET | 300 | 1.28 |
| 01:57 ET | 3361 | 1.28 |
| 02:04 ET | 100 | 1.2811 |
| 02:06 ET | 100 | 1.2899 |
| 02:13 ET | 100 | 1.28 |
| 02:20 ET | 250 | 1.28 |
| 02:27 ET | 100 | 1.29 |
| 02:29 ET | 2100 | 1.285 |
| 02:31 ET | 100 | 1.285 |
| 02:36 ET | 100 | 1.28 |
| 02:38 ET | 300 | 1.28 |
| 02:42 ET | 200 | 1.2851 |
| 02:45 ET | 2300 | 1.29 |
| 02:47 ET | 100 | 1.28 |
| 02:51 ET | 369 | 1.2899 |
| 02:54 ET | 100 | 1.28 |
| 03:00 ET | 100 | 1.28 |
| 03:12 ET | 1200 | 1.285 |
| 03:18 ET | 100 | 1.28 |
| 03:20 ET | 1400 | 1.285 |
| 03:23 ET | 100 | 1.28 |
| 03:27 ET | 100 | 1.28 |
| 03:32 ET | 3595 | 1.285 |
| 03:36 ET | 4163 | 1.2913 |
| 03:38 ET | 11100 | 1.31 |
| 03:41 ET | 200 | 1.3099 |
| 03:48 ET | 2150 | 1.3 |
| 03:50 ET | 650 | 1.305 |
| 03:52 ET | 3100 | 1.3002 |
| 03:54 ET | 300 | 1.305 |
| 03:56 ET | 826 | 1.3 |
| 03:57 ET | 3854 | 1.29 |
| 03:59 ET | 6804 | 1.3 |
Sep 20, 2024
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Friday Sep 20, 2024 by Dow Jones
4:30PM ET on Friday Sep 20, 2024 by Dow Jones
Sep 18, 2024
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs, from 8:00AM ET on Wednesday Sep 18, 2024 by Dow Jones
8:00AM ET on Wednesday Sep 18, 2024 by Dow JonesPress Release: Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs, from 8:00AM ET on Wednesday Sep 18, 2024 by Dow Jones
8:00AM ET on Wednesday Sep 18, 2024 by Dow Jones
Sep 5, 2024
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference, from 8:00AM ET on Thursday Sep 05, 2024 by Dow Jones
8:00AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tempest Therapeutics Inc | 32.8M | -0.8x | --- |
Xilio Therapeutics Inc | 33.1M | -0.4x | --- |
Surrozen Inc | 33.1M | -0.5x | --- |
Ocean Biomedical Inc | 32.2M | -0.3x | --- |
Acurx Pharmaceuticals Inc | 32.0M | -1.7x | --- |
LianBio | 31.9M | -0.4x | --- |
Company Information
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
Contact Information
- Headquarters
- 2000 SIERRA POINT PARKWAY, SUITE 400BRISBANE, CA, United States 94005
- Phone
- 415-798-8589
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Michael Raab
- President, Chief Executive Officer, Director
- Stephen Brady
- Executive Vice President, Chief Medical Officer
- Samuel Whiting
- Vice President - Strategy and Finance, Corporate Secretary
- Nicholas Maestas
- Vice President - Regulatory Affairs
- Sheldon Mullins
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $32.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 25.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.84 |
EPS | $-1.64 |
Book Value | $1.21 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
